Treatment of 5/6 nephrectomy rats with sulodexide: A novel therapy for chronic renal failure

Acta Pharmacologica Sinica

Volumn 33, Issue 5, 2012, Pages 644-651

  Li, Ping ^a   Ma, Lin Lin ^a,b   Xie, Ru Juan ^a,b   Xie, Yuan Sheng ^a   Wei, Ri Bao ^a   Yin, Min ^a   Wang, Jian Zhong ^a   Chen, Xiang Mei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

5 6 nephrectomy; Chronic renal failure; Endothelial nitric oxide synthase (eNOS); Irbesartan; Sulodexide; Tissue type plasminogen activator (tPA); aminopeptidase P(JG 12); vascular endothelium

Indexed keywords

AMINOPEPTIDASE P; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IRBESARTAN; MESSENGER RNA; SULODEXIDE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; MALE; NEPHRECTOMY; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; SHAM FEEDING; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BLOTTING, WESTERN; BODY WEIGHT; CREATININE; DISEASE MODELS, ANIMAL; FIBROSIS; GLYCOSAMINOGLYCANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; NEPHRECTOMY; NITRIC OXIDE SYNTHASE TYPE III; PROTEINURIA; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLEROSIS; TETRAZOLES; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 84860769892     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.2     Document Type: Article

References (32)

1. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-55.
2. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806-16. (Pubitemid 34183950)
3. Gadola L, Noboa O, Márquez MN, Rodriguez MJ, Nin N, Boggia J, et al. Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 2004; 65: 1224-30. (Pubitemid 38406960)
4. Vásquez J, Mathison Y, Romero-Vecchione E, Suárez C. Effect of sulodexide on aortic vasodilation capacity and associated morphological changes in rats with streptozotocin-induced diabetes. Invest Clin 2010; 51: 467-77.
5. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M, et al. Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000; 11: 2324-36.
6. Shah SV. Progress toward novel treatments for chronic kidney disease. J Ren Nutr 2010; 20: S122-6.
7. Cirujeda JL, Granado PC. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology 2006; 57: 53-64.
8. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V, et al. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002; 87: 947-52. (Pubitemid 34624874)
9. Karö J, Połubinska A, Antoniewicz AA, Sumiska-Jasiska K, Breborowicz A. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif 2007; 25: 510-4. (Pubitemid 351194897)
10. Fracasso A, Baggio B, Masiero M, Bonfante L, Bazzato G, Feriani M, et al. Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit Dial Int 2003; 23: 595-9. (Pubitemid 37527307)
11. Crepaldi G, Fellin R, Calabrò A, Baiocchi MR, Rossi A, Lenzi S, et al. Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial. Monogr Atheroscler 1986; 14: 215-21.
12. Radhakrishnamurthy B, Sharma C, Bhandaru RR, Berenson GS, Stanzani L, Mastacchi R. Studies of chemical and biologic properties of a fraction of sulodexide, a heparin-like glycosaminoglycan. Atherosclerosis 1986; 60: 141-9. (Pubitemid 16053884)
13. Skrha J, Perusicová J, Kvasnicka J, Hilgertová J. The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus. Sb Lek 1998; 99: 103-9.
14. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev 1998; 18: 1-20. (Pubitemid 28037477)
15. Perico N, Codreanu I, Schieppati A, Remuzzi G. Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago? Kidney Int Suppl 2005; S21-4.
16. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-93. (Pubitemid 11033923)
17. Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, Fukami K, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007; 18: 1525-33. (Pubitemid 46717519)
18. Tsunenari I, et al. Renoprotective effects of telmisartan in the 5/6 nephrectomised rats. J Renin Angiotensin Aldosterone Syst 2007; 8: 93-100. (Pubitemid 47272472)
19. Hostetter TH, Olson JL, Rennke HG., Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001; 12: 1315-25. (Pubitemid 32472647)
20. Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs 2007; 67: 2681-96. (Pubitemid 350224379)
21. Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2008; 23: 1946-54. (Pubitemid 351768152)
22. Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlová M, Olsovsky J, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13: 1615-25. (Pubitemid 34579250)
23. Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M, et al. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005; 18: 568-74. (Pubitemid 41824477)
24. Lambers Heerspink HJ, Fowler MJ, Volgi J, Reutens AT, Klein I, Herskovits TA, et al. Rationale for and study design of the sulodexide trials in type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet Med 2007; 24: 1290-5. (Pubitemid 47621802)
25. Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 1997; 12: 2295-300. (Pubitemid 27474610)
26. Kristova V, Liskova S, Sotnikova R, Vojtko R, Kurtansky A. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res 2008; 57: 491-4.
27. Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53: 2646-55.
28. Ciszewicz M, Polubinska A, Antoniewicz A, Suminska-Jasinska K, Breborowicz A. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res 2009; 153: 118-23.
29. Sulikowska B, Olejniczak H, Muszýska M, Odrowaz-Sypniewska G, Gaddi A, Savini C, et al. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol 2006; 26: 621-8. (Pubitemid 46143884)
30. Messa G., La Placa G., Puccetti L, Di Perri T. Effectiveness and tolerability of heparan sulfate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide. Minerva Cardioangiol 1997; 45: 147-53. (Pubitemid 27186449)
31. Kristová V, Kriska M, Babál P, Djibril MN, Slámová J, Kurtansky A. Evaluation of endothelium-protective effects of drugs in experimental models of endothelial damage. Physiol Res 2000; 49: 123-8. (Pubitemid 30111305)
32. Kristova V, Kriska M. Endothelial diseases and endothelium-protective agents. Bratisl Lek Listy 1998; 99: 511-7.